Bioactive peptides derived from human milk proteins - mechanisms of action

Journal of Nutritional Biochemistry

Volumn 25, Issue 5, 2014, Pages 503-514

  Wada, Yasuaki ^a,b   Lönnerdal, Bo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MORINAGA MILK INDUSTRY CO LTD   (Japan)

Author keywords

Bioactive peptide; Casein; Gastrointestinal digestion; Human milk; Lactoferrin; Lactalbumin

Indexed keywords

ALPHA LACTALBUMIN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; BRADYKININ; CASEIN; DIPEPTIDYL CARBOXYPEPTIDASE; FUCOSE; GALACTOSE; GLYCOPROTEIN; KAPPA CASEIN; KININOGEN; LACTOFERRIN; MILK PROTEIN; N ACETYLGALACTOSAMINE; N ACETYLGLUCOSAMINE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE PEPTIDE; PHOSPHOPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PREBIOTIC AGENT; RENIN; SIALIC ACID; ANTIOXIDANT; CASEINOMACROPEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOLOGICAL ADJUVANT; PEPTIDE; PEPTIDE FRAGMENT;

ANALGESIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; BACTERICIDAL ACTIVITY; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM INFANTIS; BREAST FEEDING; BREAST MILK; CARBOHYDRATE ANALYSIS; CENTRAL NERVOUS SYSTEM; DIFFUSION; DIGESTION; ELEVATED BLOOD PRESSURE; ENZYME INHIBITION; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRACT FUNCTION; HUMAN; IMMUNOMODULATION; INTESTINE ABSORPTION; INTESTINE INNERVATION; KALLIKREIN KININ SYSTEM; MILK; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN ANALYSIS; REVIEW; TRANSCYTOSIS; AMINO ACID SEQUENCE; ANIMAL; BOVINE; CHEMISTRY; MOLECULAR GENETICS;

BOVINAE;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIOXIDANTS; CASEINS; CATTLE; HUMANS; INTESTINAL ABSORPTION; LACTOFERRIN; MILK PROTEINS; MOLECULAR SEQUENCE DATA; OPIOID PEPTIDES; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHOPEPTIDES;

EID: 84897957309     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.10.012     Document Type: Review

References (172)

1. Gartner L.M., Morton J., Lawrence R.A., Naylor A.J., O'Hare D., Schanler R.J., et al. Breastfeeding and the use of human milk. Pediatrics 2005, 115:496-506.
2. Owen C.G., Whincup P.H., Odoki K., Gilg J.A., Cook D.G. Infant feeding and blood cholesterol: a study in adolescents and a systematic review. Pediatrics 2002, 110:597-608.
3. Owen C.G., Martin R.M., Whincup P.H., Smith G.D., Cook D.G. Effect of infant feeding on the risk of obesity across the life course: a quantitative review of published evidence. Pediatrics 2005, 115:1367-1377.
4. Owen C.G., Martin R.M., Whincup P.H., Smith G.D., Cook D.G. Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence. Am J Clin Nutr 2006, 84:1043-1054.
5. Lönnerdal B. Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr 2003, 77:1537S-1543S.
6. Patton S., Huston G.E. A method for isolation of milk fat globules. Lipids 1986, 21:170-174.
7. Williamson S., Finucane E., Ellis H., Gamsu H.R. Effect of heat treatment of human milk on absorption of nitrogen, fat, sodium, calcium, and phosphorus by preterm infants. Arch Dis Child 1978, 53:555-563.
8. Heitlinger L.A., Lee P.C., Dillon W.P., Lebenthal E. Mammary amylase: a possible alternate pathway of carbohydrate digestion in infancy. Pediatr Res 1983, 17:15-18.
9. Lindberg T., Ohlsson K., Weström B. Protease inhibitors and their relation to protease activity in human milk. Pediatr Res 1982, 16:479-483.
10. Hansen M., Sandström B., Lönnerdal B. The effect of casein phosphopeptides on zinc and calcium absorption from high phytate infant diets assessed in rat pups and Caco-2 cells. Pediatr Res 1996, 40:547-552.
11. Lönnerdal B., Glazier C. Calcium binding by α-lactalbumin in human milk and bovine milk. J Nutr 1985, 115:1209-1216.
12. Ren J., Stuart D.I., Acharya K.R. α-Lactalbumin possesses a distinct zinc binding site. J Biol Chem 1993, 268:19292-19298.
13. Suzuki Y.A., Shin K., Lönnerdal B. Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 2001, 40:15771-15779.
14. Adkins Y., Lönnerdal B. Mechanisms of vitamin B(12) absorption in breast-fed infants. J Pediatr Gastroenterol Nutr 2002, 35:192-198.
15. Goldman A.S. The immune system of human milk: antimicrobial, antiinflammatory and immunomodulating properties. Pediatr Infect Dis J 1993, 12:664-671.
16. Farnaud S., Evans R.W. Lactoferrin - a multifunctional protein with antimicrobial properties. Mol Immunol 2003, 40:395-405.
17. Ellison R.T., Giehl T.J. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991, 88:1080-1091.
18. Strömqvist M., Falk P., Bergström S., Hansson L., Lönnerdal B., Normark S., et al. Human milk κ-casein and inhibition of Helicobacter pylori adhesion to human gastric mucosa. J Pediatr Gastroenterol Nutr 1995, 21:288-296.
19. Shin K., Hayasawa H., Lönnerdal B. Purification and quantification of lactoperoxidase in human milk with use of immunoadsorbents with antibodies against recombinant human lactoperoxidase. Am J Clin Nutr 2001, 73:984-989.
20. Azuma N., Yamauchi K., Mitsuoka T. Bifidus growth-promoting activity of a glycomacropeptide derived from human κ-casein. Agric Biol Chem 1984, 48:2159-2162.
21. Liepke C., Adermann K., Raida M., Mägert H.J., Forssmann W.G., Zucht H.D. Human milk provides peptides highly stimulating the growth of bifidobacteria. Eur J Biochem 2002, 269:712-718.
22. Garofalo R. Cytokines in human milk. J Pediatr 2010, 156:S36-S40.
23. Lönnerdal B., Jiang R., Du X. Bovine lactoferrin can be taken up by the human intestinal lactoferrin receptor and exert bioactivities. J Pediatr Gastroenterol Nutr 2011, 53:606-614.
24. Liao Y., Jiang R., Lönnerdal B. Biochemical and molecular impacts of lactoferrin on small intestinal growth and development during early life. Biochem Cell Biol 2012, 90:476-484.
25. Grosvenor C.E., Picciano M.F., Baumrucker C.R. Hormones and growth factors in milk. Endocr Rev 1993, 14:710-728.
26. Savino F., Liguori S.A., Lupica M.M. Adipokines in breast milk and preterm infants. Early Hum Dev 2010, 86(Suppl 1):77-80.
27. Korhonen H., Pihlanto A. Bioactive peptides: production and functionality. Int Dairy J 2006, 16:945-960.
28. Korhonen H. Milk-derived bioactive peptides: from science to applications. J Funct Foods 2009, 1:177-187.
29. Roufik S., Gauthier S.F., Turgeon S.L. In vitro digestibility of bioactive peptides derived from bovine β-lactoglobulin. Int Dairy J 2006, 16:294-302.
30. Shimizu M. Food-derived peptides and intestinal functions. Biofactors 2004, 21:43-47.
31. Aito-Inoue M., Lackeyram D., Fan M.Z., Sato K., Mine Y. Transport of a tripeptide, Gly-Pro-Hyp, across the porcine intestinal brush-border membrane. J Pept Sci 2007, 13:468-474.
32. Saito H., Inui K. Dipeptide transporters in apical and basolateral membranes of the human intestinal cell line Caco-2. Am J Physiol 1993, 265:G289-G294.
33. Heyman M., Desjeux J.F. Significance of intestinal food protein transport. J Pediatr Gastroenterol Nutr 1992, 15:48-57.
34. Sai Y., Kajita M., Tamai I., Wakama J., Wakamiya T., Tsuji A. Adsorptive-mediated endocytosis of a basic peptide in enterocyte-like Caco-2 cells. Am J Physiol 1998, 275:G514-G520.
35. Shimizu M., Tsunogai M., Arai S. Transepithelial transport of oligopeptides in the human intestinal cell, Caco-2. Peptides 1997, 18:681-687.
36. Satake M., Enjoh M., Nakamura Y., Takano T., Kawamura Y., Arai S., et al. Transepithelial transport of the bioactive tripeptide, Val-Pro-Pro, in human intestinal Caco-2 cell monolayers. Biosci Biotechnol Biochem 2002, 66:378-384.
37. Quirós A., Dávalos A., Lasunción M.A., Ramos M., Recio I. Bioavailability of the antihypertensive peptide LHLPLP: transepithelial flux of HLPLP. Int Dairy J 2008, 18:279-286.
38. Jackson J.G., Janszen D.B., Lönnerdal B., Lien E.L., Pramuk K.P., Kuhlman C.F. A multinational study of α-lactalbumin concentrations in human milk. J Nutr Biochem 2004, 15:517-521.
39. Silva S.V., Malcata F.X. Caseins as source of bioactive peptides. Int Dairy J 2005, 15:1-15.
40. Heine W.E., Klein P.D., Reeds P.J. The importance of α-lactalbumin in infant nutrition. J Nutr 1991, 121:277-283.
41. Lönnerdal B. Bioactive proteins in human milk: mechanisms of action. J Pediatr 2010, 156:S26-S30.
42. Lien E.L. Infant formulas with increased concentrations of α-lactalbumin. Am J Clin Nutr 2003, 77:1555S-1558S.
43. Tomita M., Wakabayashi H., Shin K., Yamauchi K., Yaeshima T., Iwatsuki K. Twenty-five years of research on bovine lactoferrin applications. Biochimie 2009, 91:52-57.
44. Mellander O. The physiological importance of the casein phosphopeptide calcium salts. II. Peroral calcium dosage of infants. Acta Soc Med Ups 1950, 55:247-255.
45. FitzGerald R.J. Potential uses of caseinophosphopeptides. Int Dairy J 1998, 8:451-457.
46. Manson W., Annan W.D. The structure of a phosphopeptide derived from β-casein. Arch Biochem Biophys 1971, 145:16-26.
47. Naito H., Kawakami A., Imamura T. In vivo formation of phosphopeptide with calcium-binding property in the small intestinal tract of the rat fed on casein. Agric Biol Chem 1972, 36:409-415.
48. Naito H., Suzuki H. Further evidence for the formation in vivo of phosphopeptide in the intestinal lumen from dietary β-casein. Agric Biol Chem 1974, 38:1543-1545.
49. Meisel H., Bernard H., Fairweather-Tait S., FitzGerald R.J., Hartmann R., Lane C.N., et al. Detection of caseinophosphopeptides in the distal ileostomy fluid of human subjects. Br J Nutr 2003, 89:351-359.
50. Lee Y.S., Noguchi T., Naito H. Intestinal absorption of calcium in rats given diets containing casein or amino acid mixture: the role of casein phosphopeptides. Br J Nutr 1983, 49:67-76.
51. Erba D., Ciappellano S., Testolin G. Effect of caseinphosphopeptides on inhibition of calcium intestinal absorption due to phosphate. Nutr Res 2001, 21:649-656.
52. Bronner F. Intestinal calcium absorption: mechanisms and applications. J Nutr 1987, 117:1347-1352.
53. +-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol 2007, 92:603-619.
54. Cosentino S., Gravaghi C., Donetti E., Donida B.M., Lombardi G., Bedoni M., et al. Caseinphosphopeptide-induced calcium uptake in human intestinal cell lines HT-29 and Caco2 is correlated to cellular differentiation. J Nutr Biochem 2010, 21:247-254.
55. Perego S., Cosentino S., Fiorilli A., Tettamanti G., Ferraretto A. Casein phosphopeptides modulate proliferation and apoptosis in HT-29 cell line through their interaction with voltage-operated L-type calcium channels. J Nutr Biochem 2012, 23:808-816.
56. Gravaghi C., Del Favero E., Cantu L., Donetti E., Bedoni M., Fiorilli A., et al. Casein phosphopeptide promotion of calcium uptake in HT-29 cells - relationship between biological activity and supramolecular structure. FEBS J 2007, 274:4999-5011.
57. Hansen M., Sandström B., Jensen M., Sørensen S.S. Casein phosphopeptides improve zinc and calcium absorption from rice-based but not from whole-grain infant cereal. J Pediatr Gastroenterol Nutr 1997, 24:56-62.
58. Narva M., Kärkkäinen M., Poussa T., Lamberg-Allardt C., Korpela R. Caseinphosphopeptides in milk and fermented milk do not affect calcium metabolism acutely in postmenopausal women. J Am Coll Nutr 2003, 22:88-93.
59. Teucher B., Majsak-Newman G., Dainty J.R., McDonagh D., FitzGerald R.J., Fairweather-Tait S.J. Calcium absorption is not increased by caseinophosphopeptides. Am J Clin Nutr 2006, 84:162-166.
60. Ferranti P., Traisci M.V., Picariello G., Nasi A., Boschi V., Siervo M., et al. Casein proteolysis in human milk: tracing the pattern of casein breakdown and the formation of potential bioactive peptides. J Dairy Res 2004, 71:74-87.
61. Mercier J.C., Chobert J.M., Addeo F. Comparative study of the amino acid sequences of the caseinomacropeptides from seven species. FEBS Lett 1976, 72:208-214.
62. Fiat A.M., Jollès P. Caseins of various origins and biologically active casein peptides and oligosaccharides: structural and physiological aspects. Mol Cell Biochem 1989, 87:5-30.
63. Nakajima K., Tamura N., Kobayashi-Hattori K., Yoshida T., Hara-Kudo Y., Ikedo M., et al. Prevention of intestinal infection by glycomacropeptide. Biosci Biotechnol Biochem 2005, 69:2294-2301.
64. Yamauchi K., Azuma N., Kobayashi H., Kaminogawa S. Isolation and properties of human κ-casein. J Biochem 1981, 90:1005-1012.
65. Chabance B., Jollès P., Izquierdo C., Mazoyer E., Francoual C., Drouet L., et al. Characterization of an antithrombotic peptide from κ-casein in newborn plasma after milk ingestion. Br J Nutr 1995, 73:583-590.
66. Chabance B., Marteau P., Rambaud J.C., Migliore-Samour D., Boynard M., Perrotin P., et al. Casein peptide release and passage to the blood in humans during digestion of milk or yogurt. Biochimie 1998, 80:155-165.
67. György P., Norris R.F., Rose C.S. Bifidus factor I. A variant of Lactobacillus bifidus requiring a special growth factor. Arch Biochem Biophys 1954, 48:193-201.
68. Salminen S., Bouley C., Boutron-Ruault M.C., Cummings J.H., Franck A., Gibson G.R., et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998, 80(Suppl 1):S147-S171.
69. Bezkorovainy A., Topouzian N. Bifidobacterium bifidus var. Int J Biochem 1981, 13:585-590.
70. Idota T., Kawakami H., Nakajima I. Growth-promoting effects of n-acetylneuraminic acid-containing substances on bifidobacteria. Biosci Biotech Biochem 1994, 58:1720-1722.
71. Brück W.M., Kelleher S.L., Gibson G.R., Nielsen K.E., Chatterton D.E., Lönnerdal B. rRNA probes used to quantify the effects of glycomacropeptide and α-lactalbumin supplementation on the predominant groups of intestinal bacteria of infant rhesus monkeys challenged with enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr 2003, 37:273-280.
72. Brück W.M., Redgrave M., Tuohy K.M., Lönnerdal B., Graverholt G., Hernell O., et al. Effects of bovine α-lactalbumin and casein glycomacropeptide-enriched infant formulae on faecal microbiota in healthy term infants. J Pediatr Gastroenterol Nutr 2006, 43:673-679.
73. Newburg D.S. Neonatal protection by an innate immune system of human milk consisting of oligosaccharides and glycans. J Anim Sci 2009, 87:26-34.
74. Borén T., Falk P., Roth K.A., Larson G., Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993, 262:1892-1895.
75. Brück W.M., Kelleher S.L., Gibson G.R., Graverholt G., Lönnerdal B.L. The effects of α-lactalbumin and glycomacropeptide on the association of CaCo-2 cells by enteropathogenic Escherichia coli, Salmonella typhimurium and Shigella flexneri. FEMS Microbiol Lett 2006, 259:158-162.
76. Kawasaki Y., Isoda H., Tanimoto M., Dosako S., Idota T., Ahiko K. Inhibition by lactoferrin and κ-casein glycomacropeptide of binding of cholera toxin to its receptor. Biosci Biotechnol Biochem 1992, 56:195-198.
77. Kawasaki Y., Isoda H., Shinmoto H., Tanimoto M., Dosako S., Idota T., et al. Inhibition by κ-casein glycomacropeptide and lactoferrin of influenza virus hemagglutination. Biosci Biotechnol Biochem 1993, 57:1214-1215.
78. Kunz C., Lönnerdal B. Human-milk proteins: analysis of casein and casein subunits by anion-exchange chromatography, gel electrophoresis, and specific staining methods. Am J Clin Nutr 1990, 51:37-46.
79. Brody E.P. Biological activities of bovine glycomacropeptide. Br J Nutr 2000, 84(Suppl 1):S39-S46.
80. Kelleher S.L., Chatterton D., Nielsen K., Lönnerdal B. Glycomacropeptide and α-lactalbumin supplementation of infant formula affects growth and nutritional status in infant rhesus monkeys. Am J Clin Nutr 2003, 77:1261-1268.
81. Szymlek-Gay E.A., Lönnerdal B., Abrams S.A., Kvistgaard A.S., Domellöf M., Hernell O. α-Lactalbumin and casein-glycomacropeptide do not affect iron absorption from formula in healthy term infants. J Nutr 2012, 142:1226-1231.
82. Yvon M., Beucher S., Guilloteau P., Le Huerou-Luron I., Corring T. Effects of caseinomacropeptide (CMP) on digestion regulation. Reprod Nutr Dev 1994, 34:527-537.
83. Pedersen N.L., Nagain-Domaine C., Mahé S., Chariot J., Rozé C., Tomé D. Caseinomacropeptide specifically stimulates exocrine pancreatic secretion in the anesthetized rat. Peptides 2000, 21:1527-1535.
84. Keogh J.B., Woonton B.W., Taylor C.M., Janakievski F., Desilva K., Clifton P.M. Effect of glycomacropeptide fractions on cholecystokinin and food intake. Br J Nutr 2010, 104:286-290.
85. Burton-Freeman B.M. Glycomacropeptide (GMP) is not critical to whey-induced satiety, but may have a unique role in energy intake regulation through cholecystokinin (CCK). Physiol Behav 2008, 93:379-387.
86. Liepke C., Zucht H.D., Forssmann W.G., Ständker L. Purification of novel peptide antibiotics from human milk. J Chromatogr B Biomed Sci Appl 2001, 752:369-377.
87. Bullen J.J., Rogers H.J., Griffiths E. Role of iron in bacterial infection. Curr Top Microbiol Immunol 1978, 80:1-35.
88. Tomita M., Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J Dairy Sci 1991, 74:4137-4142.
89. Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K., Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1992, 1121:130-136.
90. Tomita M., Takase M., Bellamy W., Shimamura S. A review: the active peptide of lactoferrin. Acta Paediatr Jpn 1994, 36:585-591.
91. Kuwata H., Yip T.T., Tomita M., Hutchens T.W. Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochim Biophys Acta 1998, 1429:129-141.
92. Gifford J.L., Hunter H.N., Vogel H.J. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 2005, 62:2588-2598.
93. Vorland L.H., Ulvatne H., Rekdal O., Svendsen J.S. Initial binding sites of antimicrobial peptides in Staphylococcus aureus and Escherichia coli. Scand J Infect Dis 1999, 31:467-473.
94. Aguilera O., Ostolaza H., Quirós L.M., Fierro J.F. Permeabilizing action of an antimicrobial lactoferricin-derived peptide on bacterial and artificial membranes. FEBS Lett 1999, 462:273-277.
95. Haukland H.H., Ulvatne H., Sandvik K., Vorland L.H. The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. FEBS Lett 2001, 508:389-393.
96. Ulvatne H., Samuelsen Ø., Haukland H.H., Krämer M., Vorland L.H. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett 2004, 237:377-384.
97. Yamauchi K., Tomita M., Giehl T.J., Ellison R.T. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 1993, 61:719-728.
98. Shin K., Yamauchi K., Teraguchi S., Hayasawa H., Tomita M., Otsuka Y., et al. Antibacterial activity of bovine lactoferrin and its peptides against enterohaemorrhagic Escherichia coli O157:H7. Lett Appl Microbiol 1998, 26:407-411.
99. Pellegrini A., Thomas U., Bramaz N., Hunziker P., von Fellenberg R. Isolation and identification of three bactericidal domains in the bovine α-lactalbumin molecule. Biochim Biophys Acta 1999, 1426:439-448.
100. Hunter H.N., Demcoe A.R., Jenssen H., Gutteberg T.J., Vogel H.J. Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob Agents Chemother 2005, 49:3387-3395.
101. Oda H., Wakabayashi H., Yamauchi K., Sato T., Xiao J.Z., Abe F., et al. Isolation of a bifidogenic peptide from the pepsin hydrolysate of bovine lactoferrin. Appl Environ Microbiol 2013, 79:1843-1849.
102. Ibrahim S.A., Bezkorovainy A. Growth-promoting factors for Bifidobacterium longum. J Food Sci 1994, 59:189-191.
103. Matsui T., Tamaya K., Seki E., Osajima K., Matsumoto K., Kawasaki T. Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system. Clin Exp Pharmacol Physiol 2002, 29:204-208.
104. Matsui T., Tamaya K., Seki E., Osajima K., Matsumo K., Kawasaki T. Absorption of Val-Tyr with in vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects. Biol Pharm Bull 2002, 25:1228-1230.
105. Foltz M., Meynen E.E., Bianco V., van Platerink C., Koning T.M., Kloek J. Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation. J Nutr 2007, 137:953-958.
106. FitzGerald R.J., Murray B.A., Walsh D.J. Hypotensive peptides from milk proteins. J Nutr 2004, 134:980S-988S.
107. Vermeirssen V., Van Camp J., Verstraete W. Bioavailability of angiotensin I converting enzyme inhibitory peptides. Br J Nutr 2004, 92:357-366.
108. Catassi C., Bonucci A., Coppa G.V., Carlucci A., Giorgi P.L. Intestinal permeability changes during the first month: effect of natural versus artificial feeding. J Pediatr Gastroenterol Nutr 1995, 21:383-386.
109. Madureira A.R., Tavares T., Gomes A.M., Pintado M.E., Malcata F.X. Invited review: physiological properties of bioactive peptides obtained from whey proteins. J Dairy Sci 2010, 93:437-455.
110. Forsyth J.S., Reilly J., Fraser C.G., Struthers A.D. Angiotensin converting enzyme activity in infancy is related to birth weight. Arch Dis Child Fetal Neonatal Ed 2004, 89:F442-F444.
111. Phelan M., Kerins D. The potential role of milk-derived peptides in cardiovascular disease. Food Funct 2011, 2:153-167.
112. Hong F., Ming L., Yi S., Zhanxia L., Yongquan W., Chi L. The antihypertensive effect of peptides: a novel alternative to drugs?. Peptides 2008, 29:1062-1071.
113. Hernández-Ledesma B., Quirós A., Amigo L., Recio I. Identification of bioactive peptides after digestion of human milk and infant formula with pepsin and pancreatin. Int Dairy J 2007, 17:42-49.
114. Maruyama S., Suzuki H. A peptide inhibitor of angiotensin-I converting enzyme in the tryptic hydrolysate of casein. Agric Biol Chem 1982, 46:1393-1394.
115. Kohmura M., Nio N., Kubo K., Minoshima Y., Munekata E., Ariyoshi Y. Inhibition of angiotensin-converting enzyme by synthetic peptides of human β-casein. Agric Biol Chem 1989, 53:2107-2114.
116. Kohmura M., Nio N., Ariyoshi Y. Inhibition of angiotensin-converting enzyme by synthetic peptide-fragments of human κ-casein. Agric Biol Chem 1990, 54:835-836.
117. Fujita H., Yokoyama K., Yoshikawa M. Classification and antihypertensive activity of angiotensin I-converting enzyme inhibitory peptides derived from food proteins. J Food Sci 2000, 65:564-569.
118. Fuglsang A., Nilsson D., Nyborg N.C. Characterization of new milk-derived inhibitors of angiotensin converting enzyme in vitro and in vivo. J Enzyme Inhib Med Chem 2003, 18:407-412.
119. s1-casein expressed in Escherichia coli. J Dairy Res 1999, 66:431-439.
120. Pihlanto-Leppälä A., Koskinen P., Piilola K., Tupasela T., Korhonen H. Angiotensin I-converting enzyme inhibitory properties of whey protein digests: concentration and characterization of active peptides. J Dairy Res 2000, 67:53-64.
121. Mizushima S., Ohshige K., Watanabe J., Kimura M., Kadowaki T., Nakamura Y., et al. Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. Am J Hypertens 2004, 17:701-706.
122. Peuhkuri K., Sihvola N., Korpela R. Diet promotes sleep duration and quality. Nutr Res 2012, 32:309-319.
123. Brantl V., Teschemacher H., Bläsig J., Henschen A., Lottspeich F. Opioid activities of β-casomorphins. Life Sci 1981, 28:1903-1909.
124. Meisel H., FitzGerald R.J. Opioid peptides encrypted in intact milk protein sequences. Br J Nutr 2000, 84:S27-S31.
125. Janecka A., Fichna J., Janecki T. Opioid receptors and their ligands. Curr Top Med Chem 2004, 4:1-17.
126. Brantl V., Teschemacher H., Henschen A., Lottspeich F. Novel opioid peptides derived from casein (β-casomorphins). 1. Isolation from bovine casein peptone. Hoppe-Seyler's Z Physiol Chem 1979, 360:1211-1216.
127. Brantl V. Novel opioid peptides derived from human β-casein: human β-casomorphins. Eur J Pharmacol 1984, 106:213-214.
128. S1-casomorphin amide). Biochem J 1996, 319:903-908.
129. Yoshikawa M., Tani F., Yoshimura T., Chiba H. Opioid-peptides from milk-proteins. Agric Biol Chem 1986, 50:2419-2421.
130. Antila P., Paakkari I., Järvinen A., Mattila M.J., Laukkanen M., Pihlanto-Leppälä A., et al. Opioid peptides derived from in-vitro proteolysis of bovine whey proteins. Int Dairy J 1991, 1:215-229.
131. Mullally M.M., Meisel H., FitzGerald R.J. Synthetic peptides corresponding to α-lactalbumin and β-lactoglobulin sequences with angiotensin-I-converting enzyme inhibitory activity. Biol Chem Hoppe Seyler 1996, 377:259-260.
132. Nurminen M.L., Sipola M., Kaarto H., Pihlanto-Leppälä A., Piilola K., Korpela R., et al. α-Lactorphin lowers blood pressure measured by radiotelemetry in normotensive and spontaneously hypertensive rats. Life Sci 2000, 66:1535-1543.
133. Kapitzke D., Vetter I., Cabot P.J. Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control. Ther Clin Risk Manag 2005, 1:279-297.
134. Svedberg J., de Haas J., Leimenstoll G., Paul F., Teschemacher H. Demonstration of β-casomorphin immunoreactive materials in in vitro digests of bovine milk and in small intestine contents after bovine milk ingestion in adult humans. Peptides 1985, 6:825-830.
135. Meisel H., Frister H. Chemical characterization of bioactive peptides from in vivo digests of casein. J Dairy Res 1989, 56:343-349.
136. Tome D., Dumontier A.M., Hautefeuille M., Desjeux J.F. Opiate activity and transepithelial passage of intact β-casomorphins in rabbit ileum. Am J Physiol 1987, 253:G737-G744.
137. Ben Mansour A., Tomé D., Rautureau M., Bisalli A., Desjeux J.F. Luminal antisecretory effects of a β-casomorphin analogue on rabbit ileum treated with cholera toxin. Pediatr Res 1988, 24:751-755.
138. Sun Z., Zhang Z., Wang X., Cade R., Elmir Z., Fregly M. Relation of β-casomorphin to apnea in sudden infant death syndrome. Peptides 2003, 24:937-943.
139. Umbach M., Teschemacher H., Praetorius K., Hirschhäuser R., Bostedt H. Demonstration of a β-casomorphin immunoreactive material in the plasma of newborn calves after milk intake. Regul Pept 1985, 12:223-230.
140. Singh M., Rosen C.L., Chang K.J., Haddad G.G. Plasma β-casomorphin-7 immunoreactive peptide increases after milk intake in newborn but not in adult dogs. Pediatr Res 1989, 26:34-38.
141. Kost N.V., Sokolov O.Y., Kurasova O.B., Dmitriev A.D., Tarakanova J.N., Gabaeva M.V., et al. β-Casomorphins-7 in infants on different type of feeding and different levels of psychomotor development. Peptides 2009, 30:1854-1860.
142. Pasi A., Mahler H., Lansel N., Bernasconi C., Messiha F.S. β-casomorphin-immunoreactivity in the brain stem of the human infant. Res Commun Chem Pathol Pharmacol 1993, 80:305-322.
143. Daniel H., Vohwinkel M., Rehner G. Effect of casein and β-casomorphins on gastrointestinal motility in rats. J Nutr 1990, 120:252-257.
144. Zoghbi S., Trompette A., Claustre J., El Homsi M., Garzón J., Jourdan G., et al. β-Casomorphin-7 regulates the secretion and expression of gastrointestinal mucins through a μ-opioid pathway. Am J Physiol Gastrointest Liver Physiol 2006, 290:G1105-G1113.
145. Martínez-Maqueda D., Miralles B., De Pascual-Teresa S., Reverón I., Muñoz R., Recio I. Food-derived peptides stimulate mucin secretion and gene expression in intestinal cells. J Agric Food Chem 2012, 60:8600-8605.
146. Taira T., Hilakivi L.A., Aalto J., Hilakivi I. Effect of β-casomorphin on neonatal sleep in rats. Peptides 1990, 11:1-4.
147. Blass E.M., Fitzgerald E. Milk-induced analgesia and comforting in 10-day-old rats: opioid mediation. Pharmacol Biochem Behav 1988, 29:9-13.
148. Chiba H., Tani F., Yoshikawa M. Opioid antagonist peptides derived from κ-casein. J Dairy Res 1989, 56:363-366.
149. Teschemacher H., Koch G., Brantl V. Milk protein-derived opioid receptor ligands. Biopolymers 1997, 43:99-117.
150. Daddaoua A., Puerta V., Zarzuelo A., Suárez M.D., Sánchez de Medina F., Martínez-Augustin O. Bovine glycomacropeptide is anti-inflammatory in rats with hapten-induced colitis. J Nutr 2005, 135:1164-1170.
151. Requena P., Daddaoua A., Martínez-Plata E., González M., Zarzuelo A., Suárez M.D., et al. Bovine glycomacropeptide ameliorates experimental rat ileitis by mechanisms involving downregulation of interleukin 17. Br J Pharmacol 2008, 154:825-832.
152. López-Posadas R., Requena P., González R., Suárez M.D., Zarzuelo A., Sánchez de Medina F., et al. Bovine glycomacropeptide has intestinal antiinflammatory effects in rats with dextran sulfate-induced colitis. J Nutr 2010, 140:2014-2019.
153. de Medina F.S., Daddaoua A., Requena P., Capitán-Cañadas F., Zarzuelo A., Dolores Suárez M., et al. New insights into the immunological effects of food bioactive peptides in animal models of intestinal inflammation. Proc Nutr Soc 2010, 69:454-462.
154. Requena P., Daddaoua A., Guadix E., Zarzuelo A., Suárez M.D., Sánchez de Medina F., et al. Bovine glycomacropeptide induces cytokine production in human monocytes through the stimulation of the MAPK and the NF-κB signal transduction pathways. Br J Pharmacol 2009, 157:1232-1240.
155. Nenci A., Becker C., Wullaert A., Gareus R., van Loo G., Danese S., et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007, 446:557-561.
156. Qualls J.E., Kaplan A.M., van Rooijen N., Cohen D.A. Suppression of experimental colitis by intestinal mononuclear phagocytes. J Leukoc Biol 2006, 80:802-815.
157. Bal dit Sollier C., Drouet L., Pignaud G., Chevallier C., Caen J., Fiat A.M., et al. Effect of κ-casein split peptides on platelet aggregation and on thrombus formation in the guinea-pig. Thromb Res 1996, 81:427-437.
158. Georgeson G.D., Szony B.J., Streitman K., Varga I.S., Kovács A., Kovács L., et al. Antioxidant enzyme activities are decreased in preterm infants and in neonates born via caesarean section. Eur J Obstet Gynecol Reprod Biol 2002, 103:136-139.
159. Baydas G., Karatas F., Gursu M.F., Bozkurt H.A., Ilhan N., Yasar A., et al. Antioxidant vitamin levels in term and preterm infants and their relation to maternal vitamin status. Arch Med Res 2002, 33:276-280.
160. Okur H., Kücükaydin M., Köse K., Kontaş O., Doǧam P., Kazez A. Hypoxia-induced necrotizing enterocolitis in the immature rat: the role of lipid peroxidation and management by vitamin E. J Pediatr Surg 1995, 30:1416-1419.
161. Winterbourn C.C., Chan T., Buss I.H., Inder T.E., Mogridge N., Darlow B.A. Protein carbonyls and lipid peroxidation products as oxidation markers in preterm infant plasma: associations with chronic lung disease and retinopathy and effects of selenium supplementation. Pediatr Res 2000, 48:84-90.
162. Friel J.K., Martin S.M., Langdon M., Herzberg G.R., Buettner G.R. Milk from mothers of both premature and full-term infants provides better antioxidant protection than does infant formula. Pediatr Res 2002, 51:612-618.
163. Friel J.K., Diehl-Jones B., Cockell K.A., Chiu A., Rabanni R., Davies S.S., et al. Evidence of oxidative stress in relation to feeding type during early life in premature infants. Pediatr Res 2011, 69:160-164.
164. Korchazhkina O., Jones E., Czauderna M., Spencer S.A. Effects of exclusive formula or breast milk feeding on oxidative stress in healthy preterm infants. Arch Dis Child 2006, 91:327-329.
165. Tsopmo A., Romanowski A., Banda L., Lavoie J.C., Jenssen H., Friel J.K. Novel anti-oxidative peptides from enzymatic digestion of human milk. Food Chem 2011, 126:1138-1143.
166. Tsopmo A., Diehl-Jones B.W., Aluko R.E., Kitts D.D., Elisia I., Friel J.K. Tryptophan released from mother's milk has antioxidant properties. Pediatr Res 2009, 66:614-618.
167. Miloudi K., Tsopmo A., Friel J.K., Rouleau T., Comte B., Lavoie J.C. Hexapeptides from human milk prevent the induction of oxidative stress from parenteral nutrition in the newborn guinea pig. Pediatr Res 2012, 71:675-681.
168. Parker F., Migliore-Samour D., Floc'h F., Zerial A., Werner G.H., Jollès J., et al. Immunostimulating hexapeptide from human casein: amino acid sequence, synthesis and biological properties. Eur J Biochem 1984, 145:677-682.
169. Berthou J., Migliore-Samour D., Lifchitz A., Delettré J., Floc'h F., Jollès P. Immunostimulating properties and three-dimensional structure of two tripeptides from human and cow caseins. FEBS Lett 1987, 218:55-58.
170. Gattegno L., Migliore-Samour D., Saffar L., Jollès P. Enhancement of phagocytic activity of human monocytic-macrophagic cells by immunostimulating peptides from human casein. Immunol Lett 1988, 18:27-31.
171. Migliore-Samour D., Floc'h F., Jollès P. Biologically active casein peptides implicated in immunomodulation. J Dairy Res 1989, 56:357-362.
172. Migliore-Samour D., Roch-Arveiller M., Tissot M., Jazziri M., Keddad K., Giroud J.P., et al. Effects of tripeptides derived from milk proteins on polymorphonuclear oxidative and phosphoinositide metabolisms. Biochem Pharmacol 1992, 44:673-680.